The US bone grafts and substitutes market is forecast to grow to $2.18bn in 2030. Credit: Shannon Fagan via Getty Images.

UK-based Renovos Biologics has been granted breakthrough device designation from the US Food and Drug Administration (FDA) for Renovite BMP-2 (bone morphogenic protein 2), a synthetic nanoclay bone fusion gel. 

Renovite BMP-2 is used as an alternative to a bone graft. The gel, which contains a growth factor BMP-2, allows precise bone formation at the specific area. The nanoclay gel ensures safe and targeted bone fusion without BMP-2 leakage, and naturally degrades as new bone forms. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

In July 2023, medical device manufacturer Biocomposites acquired a minority stake in Renovos for an undisclosed sum, to advance Renovite towards pre-market approval as a carrier for orthopaedic, spine and trauma applications.  

Biocomposites made a series of acquisitions last year, including bone graft substitute manufacturer Artoss. Germany-based Artoss developed a synthetic degradable bone graft substitute called NanoBone, which consists of unsintered nanocrystalline hydroxyapatite and silica gel. 

In the announcement accompanying the breakthrough device designation for Renovite BMP-2, Biocomposites’s CEO Michael Harris said: “The granting of FDA breakthrough device Ddsignation is a transformational step for Renovos, supporting its goal to rapidly develop and bring to market Renovite – a next-generation drug carrier.” 

According to a market model on GlobalData’s Medical Intelligence Center, the US bone grafts and substitutes market is anticipated to grow from $1.91bn in 2025 to $2.18bn in 2030.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GlobalData is the parent company of Medical Device Network. 

There have been several developments over the last year in the bone graft sector. At the end of November 2023, Dimension Inx treated the first patient with its FDA-approved 3D-printed regenerative bone graft product. 

In May 2023, the FDA granted a breakthrough device design for Locate Bio’s bone graft technology for patients with degenerative disc disease (DDD). The bone graft releases a protein that drives cell differentiation and bone formation called osteoinductive recombinant human bone morphogenetic protein 2 (rhBMP-2).